Prostacyclin and stable analogs have shown beneficial effects in treating patients with critical limb ischemia. By using multiple imaging techniques, we have shown here that a stable prostacyclin analog, carbaprostacyclin (cPGI2), improves local perfusion by enhancing the growth of arteriolar networks. Our results provide the first evidence that the cPGI2-peroxisome proliferator-activated receptor β/δ axis positively affects acidic fibroblast growth factor protein expression in skeletal myotubes and smooth muscle cells. Together, the data suggest local delivery of cPGI2 exerts its therapeutic effects at the level of the arteriolar circulation.
C ritical limb ischemia (CLI) occurs in response to arterial occlusion, which leads to insufficient blood supply to the lower extremity. 1, 2 Conventional treatments for CLI are less effective when CLI progresses and causes obstruction of arterioles. In such cases, patients may develop untreatable claudication, rest pain, and ulcers that can progress to gangrene and other infections requiring amputation of the lower limb. 3, 4 New therapeutic approaches are needed to promote arteriolar growth, which potentially could reroute nutrient blood to the ischemic region and reduce peripheral resistance distal to the occlusion.
Prostacyclin (PGI2) has several favorable properties that could be used in CLI therapy. As a vasoactive drug, PGI2 is an important mediator of vascular homeostasis 5, 6 and also inhibits thrombosis and platelet aggregation. Because PGI2 is chemically unstable and has a short circulating half-life of 1 to 2 minutes, stable analogs have been developed for clinical use. 7, 8 PGI2 and its stable analogs exert their actions by interacting with the surface PGI2 receptor (IP) or nuclear peroxisome proliferator-activated receptor β/δ (PPARβ/δ). [9] [10] [11] Although PGI2 limits inward vessel remodeling, such as neointima formation and atherosclerosis, little is known about its action on adaptive outward remodeling such as growth of arterioles. Furthermore, we and others have shown the positive effect of PGI2 and its stable analogs on angiogenesis, 12, 13 in which the PPARβ/δ signaling pathway plays a critical role. However, the specific role of PGI2 in adaptive arteriolar growth is unknown.
In the current study, we created a hindlimb ischemia model to study the vascular protective effect of the stable PGI2 analog and PPARβ/δ agonist carbaprostacyclin (cPGI2). We tested the hypothesis that cPGI2 promotes arteriolar growth in hindlimb ischemia. To achieve the maximal drug effect Abstract-Prostacyclin and its stable analogs play an important vascular protective role by promoting angiogenesis, but their role in arteriolar growth is unclear. Here, we examined the effect of prostacyclin stable analog carbaprostacyclin on arteriolar growth in mouse hindlimb ischemia. Using an osmotic-controlled release system to continuously deliver carbaprostacyclin or saline (control) to ischemic mouse hindlimbs for up to 14 days, we found that blood perfusion was significantly better at 7 and 14 days in carbaprostacyclin-treated mice than in saline-treated mice. Microscopic examination of the microvasculature showed more morphological signs of arteriolar formation in carbaprostacyclin-versus saline-treated legs. A double-blind, quantitative microcomputed tomography analysis indicated that carbaprostacyclintreated legs had markedly increased vascular volume and small-to medium-sized vessel numbers that correspond to decreased vessel separation. A proteome profiler antibody array demonstrated that carbaprostacyclin-treated ischemic muscles secreted significantly higher amounts of acidic fibroblast growth factor and other chemokines. Conditioned media containing those secreted factors promoted smooth muscle cell growth and migration. Additionally, increased acidic fibroblast growth factor protein levels were detected in smooth muscle cells and skeletal myotubes at different time periods after carbaprostacyclin treatment. Furthermore, the selective peroxisome proliferation-activated receptor β/δ antagonist significantly suppressed carbaprostacyclin-induced acidic fibroblast growth factor protein production. Collectively, our data provide the first morphological and molecular evidence that local delivery of carbaprostacyclin promotes vascular growth in hindlimb ischemia, and that peroxisome proliferation-activated receptor β/δ signaling plays a critical role in inducing acidic fibroblast growth factor expression. Key Words: acidic fibroblast growth factor ■ arterioles ■ carbaprostacyclin ■ hindlimb ischemia ■ peroxisome proliferator-activated receptor β/δ ■ prostacyclin within the target tissue, we used an osmotically controlled release system to selectively deliver cPGI2 or saline (control) to the ischemic leg. We used multiple imaging techniques to assess the vascular effects of cPGI2 compared with saline on the microvascular network of ischemic legs. Our results demonstrated that the constant local release of cPGI2 in ischemic hindlimbs promotes vascular remodeling. In addition, we showed that the cPGI2-PPAR β/δ axis is involved in promoting arteriolar growth.
Methods
Detailed methods are available in the online-only Data Supplement.
Results cPGI2 Treatment Improves Perfusion and Promotes Arteriolar Growth in Hindlimb Ischemia
To examine whether cPGI2 enhances perfusion, we compared the efficacy of local delivery of cPGI2 or saline in restoring blood flow in ischemic hindlimbs. We measured blood perfusion before and after ligation of the femoral artery, 24 hours after treatment, and up to 14 days thereafter. Figure S1 in the online-only Data Supplement shows the representative colorcoded images and quantitative raw data analysis of hindlimb perfusion. At 7 days after surgery, laser Doppler-derived data showed that blood perfusion was significantly better in cPGI2-treated mice than in saline-treated mice (58.80±5.74% versus 40.60±3.14%, respectively; P<0.05; n=5/group; Figure 1A) Figure 1A ). There were no significant differences (P>0.05) between groups in systolic pressure, mean arterial pressure, heart rate, or tail blood volume before or during the treatment period ( Figure S2 ). In live mice, we microscopically examined the dynamic changes in the microvascular morphology of the limb region distal to the ligation where cPGI2 was applied. Three days after treatment, more microvascular rearrangement was observed in the cPGI2-treated group than in the saline-treated group ( Figure S3 ). Consistent with our 3-day findings, we noted more distinct structural remodeling at the arteriolar level in the cPGI2 group than in the saline group at 7 days ( Figure  S4 ), including tortuosity of arteriolar-to-arteriolar connections (white arrows, Figure S4D versus S4B, respectively), and increased intersecting of adjacent arterioles (blue arrows, Figure S4D versus S4B) in cPGI2-treated legs. Arteriolar networks were identified by their branching out from a large feeder femoral artery and from the saphenous branch of the descending genicular artery.
Because PGI2 and its analogs are short-acting vasodilators, 14 we used 2 independent approaches to evaluate whether the different configuration of vascular structures between cPGI2-and saline-treated ischemic legs was a result of cPGI2-induced vasodilation. First, we simultaneously applied cPGI2 to the anterolateral thigh muscle of the left limb and saline to the right limb in the same mouse for 24 hours; ischemia was not induced in either hindlimb. Interestingly, microscopic examination of live mice at 24 hours showed no visible differences in the preexisting microvascular network of cPGI2-treated legs compared with saline-treated contralateral legs ( Figure S5A and S5B) . Moreover, we did not observe a corkscrew-like pattern of arterioles or welldeveloped arteriolar connections. In the second approach, we compared the vasculature in the same ischemic anterolateral thigh before and 20 minutes after the constant application of cPGI2. As seen in the first approach, the acute application of cPGI2 did not enhance the visibility of the vasculature, and the morphology was similar with and without cPGI2 administration ( Figure S5C and S5D) . Together, our data suggest that arteriolar growth, not vasodilation, accounts for the differences observed in the vascular network in cPGI2-treated ischemic hindlimbs at 3 and 7 days.
cPGI2 Treatment Positively Affects Remodeling of the Microvascular Network in Ischemic Hindlimbs
We used high-definition, volumetric, quantitative micro-computed tomography (CT) to assess the overall microvascular geometry of ischemic and contralateral nonischemic legs at 14 days after femoral occlusion and constant local administration of cPGI2 or saline in ischemic legs. Bones were decalcified during sample preparation to eliminate interference during visualization of the microvasculature. We evaluated 4 different morphological properties in a double-blind manner. Supporting the perfusion data presented above, we found that the vascular volume of cPGI2-treated legs was significantly higher than that of saline-treated legs (41.28±2.22 versus 27.11±2.85 mm 3 ; P<0.05; n=5/group; Figure 1B ). In addition, cPGI2-treated legs had significantly more blood vessels (0.16±0.014 versus 0.09±0.011 1/mm; P<0.05; n=5/group; Figure 1C ) and less vessel separation (distance between vessels, 6.60±0.52 versus 10.15±1.14 mm; P<0.05; n=5/group; Figure 1D ) than did saline-treated legs. These findings suggest better development of the vascular system in the cPGI2-treated group than in the saline-treated group. We also found a positive but not significant effect on average connectivity (n=5/group; Figure 1E ) in cPGI2 versus saline groups. Similar global morphometric analyses were used to evaluate contralateral nonischemic legs. No significant differences were observed between cPGI2 and saline groups in any of the 4 morphological variables ( Figure S6A-S6D ).
To further verify the proarteriogenic effect of cPGI2, we generated a quantitative histogram by using micro-CT to illustrate the frequency and distribution of blood vessel size in cPGI2-treated and saline-treated ischemic legs and contralateral nonischemic legs. Compared with saline-treated ischemic legs, cPGI2-treated ischemic legs showed a significant increase in small vessels, with vessel diameter bins ranging from 40 to 60 μm (P<0.05; n=5/group; Figure 1F ). These data strongly indicate that cPGI2 improves perfusion, in part, by arteriogenic rather than dilatory effects because dilation would cause an increase in the diameter of all-sized vessels, not just small vessels. 15 Representative micro-CT images of vessel remodeling of cPGI2-and saline-treated limbs showed that vascular remodeling is more prominent in the region of cPGI2 delivery than in the similar anatomic location of saline delivery ( Figure 1G ). We similarly evaluated contralateral nonischemic legs and found no significant differences in vessel distribution in the cPGI2 and saline groups ( Figure  S6E ). Figure S6F shows representative micro-CT images of the vasculature in contralateral nonischemic limbs of cPGI2-and saline-treated groups. Together, these data indicate that increased vessel formation is an important means by which cPGI2 improves perfusion in ischemic legs.
Acidic Fibroblast Growth Factor and Other Cytokines Released From cPGI2-Treated Ischemic Hindlimbs Increase Smooth Muscle Cell Growth and Migration
To help determine how cPGI2 affects arteriolar growth, we performed a proteome profiler array to assess the simultaneous secretion of chemokines and soluble factors from ischemic thigh tissues 3 days after treatment with cPGI2 or saline ( Figure  S7 ). Of the 53 factors measured in the array (Figure 2A ), acidic fibroblast growth factor (fibroblast growth factor-1, FGF1), insulin-like growth factor binding protein-1, pentraxin-3, and plasminogen activator inhibitor-1 were significantly increased in cPGI2-treated thigh muscles as compared with saline-treated samples (n=3/group; Figure 2B ). Collectively, our array results suggest that multiple mediators within the local environment may affect vessel growth.
Because vascular smooth muscle cells (SMCs) are the major cellular component of arterioles, we evaluated the paracrine effect of factors released by cPGI2-and saline-treated ischemic thigh tissue on the proliferation and migration of SMCs. SMCs were cultured for 48 hours in conditioned medium (CM) from cPGI2-or saline-treated ischemic thigh tissues; the number of SMCs was significantly higher after treatment with cPGI2-CM than with saline-CM ( Figure 2C ). We then used a scratch wound migration assay to determine the effects of CM on SMC migration. Incubation with cPGI2-CM significantly increased SMC migration over that seen with saline-CM ( Figure 2D and 2E). Thus, cPGI2 treatment created a favorable microenvironment for SMC growth and migration.
cPGI2 Induces Expression of FGF1 in Skeletal Myotubes and Vascular SMCs Under Hypoxia
Because our array showed an increase in FGF1 levels in cPGI2-treated limb tissues and FGF1 seems to promote the growth of arterioles in hindlimb ischemia, 16 we focused our investigation on how cPGI2 regulates FGF1 and on the types of cells that are responsible for increased FGF1 levels. Myofibers are the main component of limb muscles; therefore, we used C2C12 myotubes to study cPGI2-mediated FGF1 expression. To mimic in vivo ischemia, we conducted these experiments in a hypoxic environment (1.5% O 2 ). At 2 hours after cPGI2 treatment, FGF1 protein levels were similar in cPGI2-treated and untreated cells. However, the expression of FGF1 in untreated cells was transient, peaking at 4 hours, and a rapid decrease was detected at 8 hours. In contrast, FGF1 expression was sustained in cPGI2-treated cells, persisting for up to 8 hours ( Figure 3A) . We also evaluated the effects of cPGI2 on FGF1 expression in vascular SMCs under similar hypoxic conditions. Treatment of SMCs with cPGI2 resulted in a more acute effect than that seen in myotubes; a marked increase in FGF1 protein levels was observed 2 hours after the addition of cPGI2 as compared with untreated SMCs ( Figure  3B ). An FGF1-positive lysate was used in parallel during Western blot ( Figure S8 ).
Because dual cellular pathways are involved in cPGI2-induced biological activities, we examined whether cell surface prostacyclin receptor (IP) signaling or nuclear receptor PPARβ/δ signaling is responsible for the increased FGF1 expression. Specific receptor antagonists were used to selectively target cPGI2-induced IP or PPARβ/δ signaling in C2C12 myotubes and SMCs. Although the IP receptor antagonist CAY-10441 (1 µmol/L) attenuated FGF1 expression in C2C12 myotubes (P>0.05) 8 hours after cPGI2 (10 µmol/L) treatment, the PPARβ/δ antagonist GSK3787 (1 µmol/L) exerted a more significant suppression on cPGI2-induced FGF1 upregulation (P<0.05; Figure 3C ). In SMCs, the IP receptor antagonist CAY-10441 did not affect FGF1 protein levels induced by cPGI2 after 2-hour treatment. However, similar treatment with the PPARβ/δ antagonist GSK3787 significantly decreased FGF1 expression ( Figure  3D ). Together, our data suggest a novel role of cPGI2-PPARβ/δ signaling in regulating FGF1 protein levels in both skeletal myotubes and SMCs under hypoxia.
cPGI2 Treatment Increases Nascent Vessel Formation in Ischemic Hindlimbs
To convert nascent vascular tubes into functional vasculature, supporting mural cells must be recruited to encircle the newly formed endothelial tube and ensure vessel survival. Mural cells interact with luminal endothelial cells of newly formed microvessels to preserve the integrity of the abluminal barrier and to facilitate cell-cell communication for vessel stabilization and maturation. To understand the role of cPGI2 on mural cell recruitment during vessel growth, we performed immunofluorescence staining to localize endothelial and mural cells within the microvasculature. We used anti-von Willebrand factor antibody to label the abluminal endothelial surface and anti-neuron-glial antigen 2 (NG2) antibody to label mural cells. NG2 is a transmembrane proteoglycan expressed exclusively by mural cells during development of the neovasculature. 17 We used laser scanning confocal microscopy to examine NG2 + mural cells around the luminal endothelial layer 7 days after arterial ligation. We found more NG2 + vessels in cross sections of anterior thigh muscles in cPGI2-treated mice than in saline-treated mice ( Figure 4A and 4B). Interestingly, most of the NG2 + arterioles were located in subcutaneous tissue and were seen underneath the muscle; these are the areas where cPGI2 was delivered (sustaining high cPGI2 concentrations) and where active vascular remodeling occurred. Quantitative analysis indicated that the number of NG2 + microvessels ranging in size from 15 to 50 µm in diameter was significantly higher in the cPGI2 group than in the saline group (38.00±2.41/high-power field versus 18.69±2.12/high-power field; P<0.01; n=3/group; Figure 4C ). To further confirm that the NG2 + cells were mural cells, we performed α-smooth muscle actin (SMA) staining and found that NG2 + vessels >15 µm in diameter coexpressed SMA ( Figure S9 ). Together, our data suggest that the controlled release of cPGI2 in ischemic hindlimbs increased the formation of NG2 + vessels. 
Discussion
In the current study, we provide evidence that local cPGI2 delivery facilitates arteriolar growth in hindlimb ischemia. We compared perfusion changes in ischemic legs after vascular occlusion and constant cPGI2 or saline delivery and found that the relative perfusion was significantly better at 7 and 14 days in cPGI2-treated legs than in saline-treated legs. Furthermore, we showed that cPGI2 treatment resulted in a more elaborate microvascular structure at the arteriolar level, distal to the ligation site, than did saline treatment. Improved blood flow in the cPGI2 group coincided with the emergence of arteriolar anastomoses, including the development of arteriolar loops adjoining arterioles and collateral vessels connecting parallel neighboring arterioles. The structural remodeling response to cPGI2 was further confirmed by double-blind micro-CT analyses. Finally, we indicated a positive role of cPGI2-PPAR β/δ signaling in regulating FGF1 protein levels in vascular SMCs and C2C12 myotubes under hypoxia.
Because cPGI2 is a vessel dilator, 18 we evaluated its dilatory effects on microvascular morphology. The hemodynamic response to prostacyclin has been shown to be measurable after a 24-hour continuous infusion of PGI2 14 ; therefore, we believe that our time point of measuring after 24 hours of cPGI2 exposure should be sufficient to view the vasodilatory effects of cPGI2 but would allow only minimal vascular growth. Interestingly, our microscopic observations showed that cPGI2 did not induce visible vasodilation; we found a similar network of microvascular structures in both cPGI2-and saline-treated legs. This finding indicates that cPGI2-induced dilatory effects cannot be seen by en face observation. Moreover, to minimize the effect of inherited morphological microvascular discrepancies between mice, we compared the microvascular morphology of left and right legs from the same mouse after local delivery of either cPGI2 or saline. Again, the application of cPGI2 in the ischemic anterolateral thigh for 20 minutes did not induce a change in the vasculature or lead to enhanced microvascular emergence when compared with the same vascular area before cPGI2 application. To our knowledge, no published studies have shown that cPGI2 can produce profound vessel relaxation resulting in a morphological change detectable via light microscopy. The vessel dilatory effect of cPGI2 has been previously observed by measuring the arteriolar response at 80 mm Hg intravascular pressure ex vivo in a vessel chamber administered with cPGI2. 19 In support of the arteriogenic role of cPGI2 shown by live animal imaging, quantitative micro-CT demonstrated that cPGI2 delivery resulted in a significant increase in the number of vessels with diameters ranging from 40 to 60 µm. This finding is the first to demonstrate cPGI2-induced arteriolar remodeling that resulted in improved perfusion in ischemic legs.
In the current report, we limited our study of cPGI2 to an acute ischemia model. An animal model that mimics the effects of the chronic ischemic disease that occurs in patients would enable us to better elucidate the therapeutic effects of cPGI2. However, creating a mouse model with chronic ischemic limbs is challenging. In the presence of arterial occlusion, angiogenesis and arteriogenesis occurs to compensate for perfusion loss. 20 Although we created severe ischemia after double ligation of the common femoral artery proximal to the origin of the femoral bifurcation, the average perfusion without drug treatment reached 54.6% at day 14 after surgery (saline-treated group, Figures 1A and S1 ). This compensatory blood recovery prevents us from examining drug function in a chronic limb ischemia model. To provide a prolonged window of time to investigate the therapeutic effects of cPGI2, we treated mice with cPGI2 immediately after surgery when minimal perfusion is observed. Using mice with a diminished ability of vascularization may enable us to establish a stable chronic ischemia model for testing drug effects.
To better understand how cPGI2 promotes microvascular remodeling in ischemic limbs, we performed a proteome profiler antibody array to screen for the expression of arteriogenic factors. Our results indicated that cPGI2 upregulates the local release of FGF1 from ischemic muscles at 3 days after femoral artery ligation. We further validated the array results by examining the effects of cPGI2 exposure on FGF1 protein levels in C2C12 myotubes and SMCs under hypoxia. We detected the presence of higher amounts of FGF1 protein in both cell types at different times after cPGI2 treatment. Overexpression of FGF1 has been shown to promote the growth of arterioles in mice by increasing the number and density of branches. 21 In a hamster model of peripheral arterial disease, FGF1 gene transfer promoted arteriogenesis in ischemic hindlimbs. 16 However, FGF1 has low thermal stability in the absence of heparin, is easily degraded by proteases, and has a short halflife in vivo. 22 Thus, the instability of FGF1 limits its biological action in therapeutic applications. Our data suggest that administration of cPGI2 may help maintain a constant FGF1 concentration for an extended period, which may compensate for FGF1's instability and increase its efficacy during the critical window of vascular remodeling.
We examined the signaling pathway involved in cPGI2-induced FGF1 protein expression under hypoxia. Our results indicate a novel role for PPARβ/δ signaling in promoting arteriolar growth. PPARβ/δ is a ligand-activated transcriptional factor that modulates target gene expression. Evidence has emerged suggesting a potential role for PPARβ/δ in prostacyclin-induced vascular protection. 13 Although the proangiogenic property of stable PGI2 analogs is attributed to PPARβ/δ activity, 23 little is known about how the PGI2-PPARβ/δ axis affects the growth or remodeling of preexisting arteriolar networks. cPGI2 is ideal for studying this issue because it functions as a stable PGI2 analog and is known to be an effective PPARβ/δ agonist. Here, we first used multiple quantitative imaging techniques to illustrate the positive effects of cPGI2 on arteriolar growth. We then found that a combination of soluble factors produced in the local tissue microenvironment of cPGI2-treated legs promotes SMC migration and growth. Furthermore, using a selective and irreversible PPARβ/δ inhibitor GSK3787, we demonstrated the positive effects of cPGI2-PPARβ/δ axis on the production of arteriogenic factor FGF1. Our results indicate a role for PPARβ/δ in adaptive vascular remodeling and suggest that PPARβ/δ may be a new therapeutic target for treating CLI.
Different mechanisms may be involved in cPGI2-induced FGF1 expression in different cell types. In SMCs, increased amounts of FGF1 were detected at 2 hours after cPGI2 treatment. This acute response depended on PPARβ/δ signaling because GSK3787 blocked the increase; this finding indicates the possibility that PPARβ/δ directly regulates the FGF1 gene. A recent study showed that the FGF1 gene promoter region contains a conserved PPAR response element. 24 Thus, PPARβ/δ might act through transcriptional activation of FGF1. Interestingly, in C2C12 myotubes, a prolonged period of time (8 hours) was required for cPGI2 to exert a positive effect on FGF1 protein expression. Moreover, treatment of myotubes with the PPARβ/δ antagonist GSK3787 did not completely block the increase in FGF1 levels. Considering that similar treatment with the IP antagonist CAY 10441 also decreased cPGI2-induced FGF1 protein levels (although statistically not significant), it is possible that IP signaling is, in part, responsible for increased FGF1 production. Therefore, a more complex mechanism involving interaction between IP and PPARβ/δ signaling may affect the upregulation of FGF1 in skeletal myotubes. In the current study, we demonstrated a novel association between cPGI2-PPARβ/δ-FGF1 signaling and arteriolar growth in ischemic hindlimbs. However, we did not rule out additional mechanisms (eg, nitric oxide pathway) that may affect cPGI2-induced arteriolar growth.
Given the finding that the secreted arteriogenic factor FGF1 is persistently present in skeletal myotubes treated with cPGI2, the paracrine action of skeletal myofibers in promoting the formation of vasculature is noteworthy. Cytokines and growth factors released from inflammatory and vascular cells stimulate vascular growth, but the role of myofibers is poorly understood. Because myofibers are a major cell type surrounding arterioles in skeletal muscles, their signaling to neighboring vascular cells (eg, endothelial cells and SMCs) may affect arteriolar growth. Such signaling may not only reestablish a sufficient vascular network to provide fuel for myofibers but also reduce myofiber necrosis during ischemia. We postulated that the paracrine action of skeletal muscles triggered by therapeutic agents in ischemic conditions is an efficient strategy to potentiate arteriolar growth and to rapidly compensate for insufficient blood supply by recruiting preexisting arteriolar networks. Supporting this idea, our findings indicate that myotubes serve as a critical effector of cPGI2 signaling and as a hub for secreting the arteriogenic factor FGF1.
In conclusion, we present comprehensive evidence that cPGI2 positively affects adaptive vascular remodeling in hindlimb ischemia. We also provide evidence that cPGI2 promotes FGF1 protein expression in SMCs and skeletal myotubes via PPARβ/δ signaling. Because PGI2 is known to inhibit vascular dysfunction (eg, thrombosis and atherosclerosis), we believe our findings will be useful in developing novel treatment strategies for atherosclerotic diseases such as CLI.
Perspectives
CLI is the severe obstruction of blood flow to the lower extremities and is caused by adverse cardiovascular conditions such as atherosclerosis, hypertension, and hypercholesterolemia. Revascularization is the best treatment strategy for CLI. Prostacyclin and stable analogs are clinically recommended agents for treating CLI and have shown beneficial effects. In the current study, we used a local drug delivery system and demonstrated a novel function of the stable prostacyclin analog carbaprostacyclin (cPGI2) in promoting revascularization in hindlimb ischemia. Using multiple imaging techniques, we showed that cPGI2 attenuates hindlimb ischemia by promoting arteriolar growth. Moreover, we uncover a novel mechanism for cPGI2-enhanced vascular remodeling. We demonstrate cPGI2-induced nuclear receptor PPARβ/δ signaling positively affects FGF1 protein levels in vascular SMCs and skeletal myotubes. Our data suggest that cPGI2 may improve the paracrine action of ischemic skeletal myofibers to enhance arteriolar growth. Because ischemia results in blood loss at the microvascular level and arterioles directly control blood distribution throughout the hindlimbs, the cPGI2-PPAR β/δ axis may serve as an effective target for inducing arteriolar growth and increasing blood flow to ischemic tissue beds. Together, the current findings will advance our understanding of the prostacyclin-mediated PPARβ/δ signaling that controls adaptive vascular remodeling in hindlimb ischemia.
What Is New?
• cPGI2 administered directly to the ischemic tissue bed improved perfusion by inducing arteriolar growth and remodeling and promoted the release of acidic fibroblast growth factor.
• Nuclear receptor peroxisome proliferator-activated receptor β/δ signaling may be the primary pathway involved in arteriolar remodeling.
What Is Relevant?
• Because of our aging population, critical limb ischemia is a major therapeutic challenge. Prostacyclin and its stable analogs are a therapeutic choice for treating critical limb ischemia, but the role of prostacyclin analogs in arteriolar growth is unknown.
• The current study facilitates further understanding of the cPGI2-peroxisome proliferator-activated receptor β/δ axis in promoting arteriolar growth and helps to formulate a new strategy for the development of therapeutic agents.
Mice (5 mice/group) were euthanized, and the thoracic cavity was opened. The right atrium was cut, and the lower abdominal aorta was ligated; the vasculature, distal to the ligation site, was flushed with 0.9% normal saline containing heparin (1000 IU/L) for 5 minutes with a syringe pump. Then, 10% neutral buffered formalin was pressure perfused for an additional 5 minutes. A contrast agent, radiopaque silicone rubber compound (Microfil, MV-112, Flow Tech Inc. Carver, MA), was injected into the abdominal aorta distal to the ligation site for 5 minutes. The mice were immediately placed into 10% neutral buffered formalin and maintained at 4°C overnight for proper polymerization of the agent. After 24 hours, the skin was removed, and the lower portion was dissected (distal to the lower abdominal aorta ligation) and placed in 10% formalin for an additional 4 days. The contralateral and ischemic hindlimbs were then dissected and placed in formic acid (Cal Ex II, Fisher Scientific, Pittsburgh, PA) for 48 hours to facilitate decalcification of bones. The hindlimbs were washed thoroughly under running water for 1 hour and then placed in 10% formalin and immediately imaged by micro-CT.
The vasculature in the hindlimb was imaged by using a high-resolution (10-28 µm isotropic voxel size) micro-CT imaging system (Explore Locus SP MicroCT, GE Healthcare; Little Chalfont, UK). The scanner was positioned to a voltage of 80 kVp and a current of 80 µA. The entire width of the field of view, imaged at a medium resolution, created an initial thumbnail reconstruction with a 458 x 458 pixel image matrix and a 70.3 µm isotropic voxel size. This thumbnail image was cropped around the hindlimb resulting in a rectangular volume that was reconstructed at 28 µm and then at 14 µm isotropic voxel size. Serial tomograms were recreated from raw data by using a cone beam filtered back projection algorithm. The tomograms were globally thresholded with a HU value of 200 and used to produce binarized 3D images of the microvasculature in the hindlimb partitioned from the surrounding tissues.
The morphologic vascular network in the 3D images of the ischemic (left) and nonischemic (right) hindlimbs was assessed for several parameters. The mouse hindlimbs were scanned and reconstructed at a 14-µm voxel size, and an isosurface threshold of 200 was chosen to be consistent with the 2-D tomograms rendered in Microview 2.0.29 (GE Healthcare). Vascular volume, number, separation, and connectivity were evaluated. These parameters were chosen on the basis of the standard outputs rendered by using a trabecular bone thickness analysis tool (BoneJ, http://bonej.org ), and those values were applied to the microvascular network of the hindlimbs. A volume of interest (VOI) was reconstructed in the upper and lower hindlimb. The vascular volume was calculated by using the generated voxel size and the number of segmented voxels in the 3D images. Vascular number and separation were computed by using the BoneJ thickness analysis tool. Connectivity was generated by using the Euler characteristic method. 5 Additionally, vessel diameter was assessed and represented the total number of vessel of a specified diameter and output in a 16-bit 3D image with corresponding grayscale values. For each hindlimb, histograms were generated with a consolidated number of bins (which correspond to vessel diameter in µm) evenly spaced from 0 to the maximum measured thickness of every point in the leg and the number of voxels that were associated with that particular bin diameter.
Conditioned Medium Collection and Proteome Profiler Array
The mice were euthanized at 3 days after constant cPGI2 or saline delivery (3 mice/group). The thigh muscle (10-11 g) was dissected and cut into small pieces (1 mm x 1 mm per piece). Muscle pieces were incubated in 1 mL of serum-free Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) supplemented with 0.1% bovine serum albumin (BSA) and 1% penicillinstreptomycin for 2 hours at 37°C. Tissue mixtures were then centrifuged for 5 minutes to eliminate tissue clumps. Conditioned medium (CM) was collected from the saline-treated group (Saline-CM) and the cPGI2-treated group (cPGI2-CM) and stored at -80°C. A proteome profiler array was performed according to the manufacturer's instructions (R&D system, Minneapolis, MN). In short, after a 1-hour membrane-blocking step, the pre-incubated CM-biotinylated antibody mixture was added, and the membrane was incubated overnight at 4°C. After a series of washes, the membrane was incubated with horseradish peroxidase-conjugated streptavidin, and the signal was detected by using ECL-Hyperfilm. Average protein expression levels were measured by using ImageJ software (rsbweb.nih.gov/ij), based on 3 independent arrays.
Smooth Muscle Proliferation and Scratch Wound Migration Assays
Mouse SMCs (MOVAS, ATCC) were seeded onto 96-well plates (2 x10 3 /well) and cultured with DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin for 24 hours in a 5% CO 2 incubator at 37°C. Cells were starved with serum-free DMEM medium containing 0.1% BSA and 1% penicillin-streptomycin for an additional 24 hours. Culture medium was then replaced with control medium (serum-free DMEM+0.1% BSA), cPGI2-CM, or saline-CM supplemented with 1% FBS and 1% penicillin-streptomycin, and cells were grown for 48 hours in a 5% CO 2 incubator at 37°C. To measure cell proliferation, cells were treated with trypsin, and Trypan blue exclusion was used to obtain a direct count of viable cells under every culture condition. The average cell number was calculated on the basis of 3 independent experiments.
Scratch wound migration was performed in laminin-coated 96-well plates (BD Biosciences). Mouse SMCs (MOVAS, 6 x 10 4 ) were seeded onto each well with DMEM containing 10% FBS. After forming a confluent layer, cells were serum-starved (DMEM + 0.1% BSA) for 18 hours. Scratches were then made with a p200 pipette tip, and cell debris was removed by washing each well once with medium (DMEM + 0.1 % BSA). Afterward, 200µl of serum-free DMEM (control), saline-CM, or cPGI2-CM, all supplemented with 1% FBS and 1% penicillin-streptomycin, was added to individual wells. The plate was placed in the incubator at 37°C and monitored for cell migration for up to 24 hours. Photographs were taken at 0 and 24 hours in the same field of view for all cell conditions. The images were quantitatively assessed with the use of Image Pro-Plus software by comparing the distances from the 0-to the 24-hour image and measuring the scratch closure difference in several areas in the well. Three independent assays were performed. C2C12 Cell Culture Six-well tissue culture plates were pre-coated with rat tail collagen overnight at 4°C (SigmaAldrich, St. Louis, MO). Approximately 4×10 5 mouse C2C12 myoblasts (ATCC) were then seeded in each well and cultured with DMEM medium containing 10% FBS and 1% penicillinstreptomycin in a 5% CO 2 incubator at 37°C. To induce differentiation into myotubes, cells were switched into DMEM medium supplemented with 2% horse serum and grown for an additional 3 days. Western Blot Analysis C2C12 myotubes and SMCs were starved with serum-free DMEM medium containing 0.1% BSA overnight, the cells were switched into a serum-free DMEM with or without 10µm carbaprostacyclin (Cayman Chemical) in a hypoxia chamber (1.5% O 2 , INVIVO 2 400, Ruskinn, UK) and incubated for 2, 4, or 8hour at 37°C. To test whether IP or PPARβ/δ signaling was involved in cPGI2-induced FGF-1 protein expression, C2C12 myotubes and SMCs were starved with serum-free DMEM medium containing 0.1% BSA overnight. Cells were then pretreated with CAY10441 (1µM, Cayman Chemical) or GSK 3787 (1µM, Sigma-Aldrich) at 37°C for 30 minutes. Afterward, 10µm carbaprostacyclin was added, and the cells were incubated for an additional 2 hours (SMCs) or 8 hours (myotubes) in a hypoxia chamber (1.5% O 2 ).
